证券代码：600056 证券简称：中国医药 公告编号：临 2025-050 号 中国医药健康产业股份有限公司 2024年度末期权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.08565元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/9 | － | 2025/7/10 | 2025/7/10 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日召开的2024年年度股东大会审议通过。 加上 2024 年中期已派发的现金红利每股 0.02174 元（含税），合计按每股 0.10739 元（含税）向全体股东派发 2024 年度现金红利，总金额为 160,642,526.14 元。 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 ...

中国医药健康产业股份有限公司股东大会会议文件 证券代码：600056 证券简称：中国医药 2025 年第四次临时股东大会 会议资料 2025 年 6 月 23 日 中国医药健康产业股份有限公司股东大会会议文件 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 中国医药健康产业股份有限公司股东大会会议文件 关于放弃参股公司24%股权优先购买权的议案 各位股东： 近日，中国医药健康产业股份有限公司(以下简称"公 司"或"中国医药")收到参股公司重庆医药健康产业有限 公司（以下简称"重庆医健"）股东重庆渝富控股集团有限 公司(以下简称"重庆渝富"，持有重庆医健 49%股权)《关于 重庆渝富控股集团有限公司拟公开挂牌转让重庆医药健康 产业有限公司股权的告知函》，重庆渝富拟采取公开挂牌方 式转让其所持重庆医健 24%股权，并就本次拟转让事项请公 司确定是否行使优先购买权。6 月 18 日，重庆渝富在重庆联 合产权交易所正式公开挂牌转让其所持重庆医健 24%股权， 公开征集受让方。挂牌公告显示，重庆渝富本次股权转让底 价为 220,611.024 万元，价款支付方式为一次性支付。 （三）标的企业情况 1 中国医药 ...

Core Insights - The second China Pharmaceutical Health Industry Development Conference was held in Zibo, focusing on innovation and integration in the pharmaceutical health sector [1][3] - The conference gathered over 2,000 industry elites, including academicians and business representatives, to discuss innovative development paths for the pharmaceutical health industry [3] Group 1: Conference Themes and Discussions - The conference theme was "Breaking Boundaries, New Integration, New Intelligence, Exploring New Models," emphasizing the need for systemic innovation in healthcare [3] - Academician Yu Jinming highlighted that high-quality hospital development relies on systemic innovation beyond mere technological breakthroughs [3] - Academician Huang Zhengming pointed out that the future of the pharmaceutical industry depends on the cultivation of "new quality productivity" in response to aging and chronic disease burdens [3] Group 2: Major Projects and Initiatives - Three significant healthcare projects were launched, including the Chronic Disease Prevention Workstation and specialized centers for pancreatic cancer and diabetes treatment [4] - These projects will leverage resources from various sectors to establish a four-tier management network and promote smart platforms and regional demonstration networks [4] Group 3: Forum and Activities - The conference featured six thematic forums covering topics such as AI empowerment, traditional Chinese medicine, minimally invasive innovations, and chronic disease prevention [4] - A "Specialty Enterprise Study" activity allowed participants to visit local pharmaceutical and healthcare facilities, while a volunteer service event provided free health consultations to the public [4] Group 4: Zibo's Role in the Industry - Zibo showcased its strong pharmaceutical industry foundation and innovative environment, demonstrating its commitment to becoming a hub for pharmaceutical health industry innovation [5] - The signing of projects and continuous resource aggregation in Zibo is expected to bring new development opportunities for the pharmaceutical health industry both locally and nationally [5]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-049 号 中国医药健康产业股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 受理号：CYHB2501162 通知书编号：2025B02882 剂型：注射剂 规格：1ml:100μg 上市许可持有人：海南通用三洋药业有限公司 药品生产企业：四川美大康佳乐药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 此次申请事项符合药品注册的有关要求，同意按照《药品上市后变更管理办法（试 行）》相关规定，批准本品上市许可持有人由"成都诺和晟鸿生物制药有限公司" 变更为"海南通用三洋药业有限公司"，药品批准文号不变。转让药品的生产场 地、处方、生产工艺、质量标准等与原药品一致，不发生变更。 二、药品其他相关情况 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用三洋药业有限公司（以下简称"三洋药业"）收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的卡 ...

金十数据6月27日讯，中国医药公告，下属全资子公司三洋药业收到国家药监局核准签发的卡贝缩宫素 注射液《药品补充申请批准通知书》。该药品用于选择性硬膜外或腰麻下剖宫产手术，以预防子宫收缩 乏力和产后出血。此次申请事项符合药品注册要求，同意变更上市许可持有人为三洋药业，药品批准文 号不变。三洋药业在该药品项目的累计投入约为393万元。2024年该药品国内销售额约为2.01亿元。三 洋药业成为该药品的上市许可持有人，进一步丰富了公司产品线，有利于提升市场竞争力。 中国医药：子公司获得药品补充申请批准 ...

Core Insights - The second China Pharmaceutical Health Industry Development Conference will be held in Zibo from June 27 to 29, 2025, gathering over 2000 industry elites [3] - The conference aims to promote the deep integration of traditional Chinese medicine with artificial intelligence and biomedicine, breaking down disciplinary barriers [3] - Key missions include reconstructing the pharmaceutical industry chain using 5G and AI, accelerating the upgrade of smart medical ecosystems, and establishing a comprehensive platform for chronic disease prevention and treatment [3] Industry Collaboration - The event is co-hosted by the China Pharmaceutical Education Association and the Shandong Provincial Pharmaceutical Industry Association, with support from various medical and research organizations [3] - The conference will feature leading scholars in the pharmaceutical field, including academicians, who will share insights through a keynote report and six thematic forums [3] Community Engagement - During the conference, a public health initiative called "Chronic Disease Prevention Health Action" will be organized, along with "Specialized Enterprise Study" sessions to promote the practical application of industry achievements [4] - The initiative aims to position Zibo as an "innovation magnet" in the pharmaceutical health industry [4]

Core Viewpoint - The training program on medical insurance capacity building for developing countries, hosted by China, marks a significant milestone in international cooperation in healthcare, focusing on sharing experiences and enhancing collaboration with African and Southeast Asian nations [1][10]. Group 1: Training Program Overview - The training program involved 50 government representatives and experts from 12 countries, emphasizing China's commitment to sharing its medical insurance experiences [1]. - The program served as a platform for discussing key issues in global healthcare, including the construction of medical insurance systems and the reduction of drug prices [3][10]. - Participants engaged in practical sessions, including site visits to Chinese medical institutions and discussions on China's centralized procurement mechanisms [1][8]. Group 2: Insights on China's Medical Insurance System - China's medical insurance system, which covers over 1.3 billion people, is viewed as a model for developing countries seeking to establish sustainable healthcare systems [5]. - The program highlighted the importance of universal coverage as a fundamental guarantee for public health, with insights shared on China's policies and mechanisms for achieving this goal [3][10]. - The training addressed various aspects of medical assistance, including the identification of beneficiaries and the role of different departments in providing support [4][10]. Group 3: Opportunities for Chinese Pharmaceutical Companies - The training facilitated connections between Chinese pharmaceutical companies and representatives from developing countries, showcasing the potential for collaboration in healthcare [6][11]. - Participants expressed interest in the quality and affordability of Chinese medical products, with discussions on the challenges and opportunities for Chinese companies to enter international markets [6][9]. - The program emphasized the strategic importance of centralized procurement in enhancing the competitiveness of Chinese medical products abroad [9][10]. Group 4: Future Collaboration and Impact - The training is seen as a bridge connecting China's medical insurance solutions with the healthcare needs of African and Southeast Asian countries, fostering long-term partnerships [11]. - Representatives from various countries expressed optimism about applying the knowledge gained to improve their own healthcare systems and enhance cooperation with China [10][11]. - The initiative is expected to contribute to addressing the challenges of "difficult and expensive medical care" in developing countries [10].

证券代码：600056 证券简称：中国医药 公告编号：临2025-047号 中国医药健康产业股份有限公司 关于放弃参股公司 24%股权优先购买权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 近日，中国医药健康产业股份有限公司(以下简称"公司")收到参股公司重 庆医药健康产业有限公司（以下简称"重庆医健"）股东重庆渝富控股集团有限公 司(以下简称"重庆渝富"，持有重庆医健49%股权)《关于重庆渝富控股集团有限公 司拟公开挂牌转让重庆医药健康产业有限公司股权的告知函》，重庆渝富拟采取公 开挂牌方式转让其所持重庆医健24%股权，并就本次拟转让事项请公司确定是否行使 优先购买权。6月18日，重庆渝富在重庆联合产权交易所正式公开挂牌转让其所持重 庆医健24%股权，公开征集受让方。挂牌公告显示，重庆渝富本次股权转让底价为 220,611.024万元。结合公司实际情况及整体工作安排，公司拟放弃重庆医健24%股 权的优先购买权。 本次重庆渝富采取公开挂牌方式转让其所持重庆医健24%股权，目前尚无法 确定受让方，本次放 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-048 号 中国医药健康产业股份有限公司 关于召开2025年第四次临时股东大会的通知 2025年第四次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 11 日 14 点 30 分 召开地点：北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 (一)股东大会类型和届次 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 11 日 至2025 年 7 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网 ...

(二)本次会议通知于2025年6月18日以邮件、短信、电话或传真的方式向全体董 事发出。因增加议案，2025年6月20日以邮件、短信或电话的方式向全体董事发出增 加议案的通知。 (三)本次会议应当出席董事8名，实际出席会议的董事8名。 证券代码：600056 证券简称：中国医药 公告编号：临2025-046号 中国医药健康产业股份有限公司 第九届董事会第 28 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第28次 会议（以下简称"本次会议"）于2025年6月23日以现场结合通讯方式召开，会议由 董事长杨光先生主持，公司监事及相关高级管理人员列席了本次会议。 经决议，董事会一致同意公司放弃重庆医药健康产业有限公司 24%股权优先购买 权事项。具体内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的临 2025-047 号公告。 表决结果：同意 8 票；反对 0 票；弃权 0 票。 （三）审议通过了《关于召开 ...